Rheumatology Biorepository
Part of paid clinical trials in Waltham, Massachusetts.
- Sponsor
- CorEvitas
- Study ID
- NCT04899895
- Status
- Enrolling By Invitation
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Study Details
The Biorepository is a prospective observational cohort study for patients under the care of a licensed physician or qualified physician extender. Target minimum enrollment is approximately 3,000 patients within the first 5 years of the study with no defined upper limit of enrollment. Sites from Corrona's current North America network will be asked to participate. Participating sites and subjects will not receive results from any laboratory testing conducted on the Samples. Personal identifying information will not be collected along with the Samples. Subjects will provide informed consent to contribute Samples to include blood (serum, plasma, whole blood) to the Biorepository. In the future, Subjects may be asked to contribute other samples (i.e. saliva, urine, stool) and an additional informed consent will be obtained. Subjects will retain the right to withdraw their consent for use of their Samples at any time. In such case, Corrona will destroy any unused/remaining Samples in its possession.
Key Dates
- Start date
- Mar 10, 2021
- Status verified
- Jan 2026
- Primary completion
- Dec 31, 2100
- Completion
- Dec 31, 2100
Study Design
- Enrollment
- 3,000 participants (estimated)
Primary Outcome Measure
1. Biospecimen (blood) Collection [ Time Frame: every 6 months for 10 years ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Corrona, LLC | Waltham | Massachusetts | 02451 | - |
Find similar trials in Waltham, MA
Related Studies
- CorEvitas Rheumatoid Arthritis (RA) Drug Safety & Effectiveness RegistryEnrolling By Invitation · CorEvitas · Waltham, Massachusetts
- Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVOPHASE1 · Recruiting · National Cancer Institute (NCI) · Birmingham, Alabama
- RA-PRO PRAGMATIC TRIALPHASE3 · Recruiting · University of Alabama at Birmingham · Auburn, Alabama
- A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)PHASE1 · Recruiting · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Aurora, Colorado